The ocrelizumab phase II extension trial suggests the potential to improve the risk:benefit balance in multiple sclerosis (Follow the link) available for 50 days
This suggests that there may be possible to maintain benefit by extending the dosing interval. We think a clinical study needs to be done to formally show this.
If you want to look at a follow on study have a look at
COVID-19 vaccine-readiness for ocrelizumab and other anti-CD20-depleting therapies in multiple sclerosis and other autoimmune diseases David Baker, Charles Roberts, Gareth Pryce, Angray Kang, Monica Marta, Saul Reyes, Klaus Schmierer, Gavin Giovannoni, Sandra Amor. Authorea DOI: 10.22541/au.159292858.82650822
This creates yet more evidence that memory B cell inhibition can link to efficacy
COI: Thanks to Roche and ClinicalStudyDataRequest.com for suplying the data.